Education
About Us
Working with TipRanks
Follow Us
American Shared Hospital Services (AMS)
:AMS
Top Page
American Shared Hospital Services
(NYSE MKT:AMS)
Select Model
Select Model
Rating:57Neutral
Price Target:
$3.00
▲(3.45% Upside)
The overall stock score of 57 reflects a mixed outlook. The most significant factor is the company's financial performance, which shows revenue growth but struggles with profitability and cash flow. Technical analysis indicates strong bullish momentum, but valuation concerns arise from a negative P/E ratio. The earnings call provided some optimism with strategic growth initiatives, but challenges remain.
American Shared Hospital Services (AMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.88M
Dividend YieldN/A
Average Volume (3M)39.44K
Price to Earnings (P/E)11.7
Beta (1Y)0.13
Revenue Growth26.61%
EPS Growth-156.30%
CountryUS
Employees81
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.04
Shares Outstanding6,510,000
10 Day Avg. Volume111,715
30 Day Avg. Volume39,440
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.94
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit5.14
Enterprise Value/Ebitda10.04
Forecast
1Y Price Target
$3.00Price Target Upside3.45% Upside
Rating ConsensusHold
Number of Analyst Covering1
American Shared Hospital Services Business Overview & Revenue Model
Company DescriptionAmerican Shared Hospital Services leases radiosurgery and radiation therapy equipment to health care providers. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides financing services for Leksell Gamma Knife units. In addition, the company offers proton beam radiation therapy services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. As of December 31, 2021, it had 115 operating Gamma Knife units located in the United States, as well as two in South America in Lima, Peru and Guayaquil, Ecuador. The company also operates one PBRT system. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California.
How the Company Makes MoneyAMS generates revenue through a rental model, where it leases advanced medical equipment to hospitals and healthcare facilities. This model allows AMS to earn consistent rental income while minimizing the capital expenditure required by healthcare institutions. Key revenue streams include leasing agreements for diagnostic imaging and radiation therapy equipment, along with maintenance and support services for the technology provided. Additionally, AMS may engage in strategic partnerships with healthcare providers, enhancing its service offerings and expanding its market reach, which further contributes to its earnings.
American Shared Hospital Services Earnings Call Summary
Earnings Call Date:Aug 13, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong sequential growth in revenue and EBITDA, driven by strategic expansion in direct patient services and international markets. However, there were notable challenges, such as declines in equipment leasing revenue and treatment volumes, leading to a net loss. Despite these challenges, the company remains confident in its long-term growth strategy.Q2-2025 Updates
Positive Updates
Sequential Revenue Growth
Second quarter 2025 revenue increased 16% sequentially from last quarter, driven by expansion of the Direct Patient Services segment and international business development initiatives.
Double-Digit Revenue Increase in Direct Patient Services
Revenue from Direct Patient Services was $3.5 million for Q2 2025, marking an increase of 12% compared to Q2 2024, driven by the Rhode Island acquisition and new operations in Puebla, Mexico.
Strong Adjusted EBITDA Growth
Q2 2025 adjusted EBITDA came in at $1.7 million compared to $949,000 in Q1 2025, showing strong cost controls and reliance on treatment volumes for growth.
Successful Expansion in International Markets
The international segment is a significant growth area with centers in Peru, Ecuador, Puebla, and a new center planned in Guadalajara, Mexico.
Strategic Partnerships and Staffing Achievements
Secured professional services agreement with Brown University Health and recruited three radiation oncologists for Rhode Island centers.
Negative Updates
Decrease in Equipment Leasing Revenue
Revenue from the Equipment Leasing segment decreased to $3.6 million from $3.9 million in Q2 2024, with declines in Gamma Knife and proton beam therapy revenues.
Year-over-Year Decline in Gamma Knife Procedures
The number of Gamma Knife procedures decreased 22% compared to Q2 2024, primarily due to the expiration of two contracts.
Operating Income and Net Loss
Q2 2025 operating income was a loss of $544,000 compared to a loss of $1,000 in Q2 2024. Net loss attributable to the company for Q2 2025 was $280,000 compared to a net income of $3.6 million in Q2 2024.
Gross Margin Decline
Gross margin for Q2 2025 decreased 34% compared to Q2 2024, reflecting increased operational expenses and lower treatment volumes.
Company Guidance
During the American Shared Hospital Services Second Quarter 2025 Earnings Conference Call, the company reported a 16% sequential increase in revenue, reaching $7.1 million, primarily attributed to the expansion of their Direct Patient Services segment and international business initiatives. The adjusted EBITDA for Q2 2025 was $1.7 million, a significant increase from $949,000 in Q1 2025. The company also highlighted a 27% increase in Gamma Knife procedures from the previous quarter, though the number was still down 22% compared to Q2 2024 due to the expiration of two contracts. The Rhode Island acquisition and the opening of a new center in Puebla, Mexico, were major contributors to the revenue growth. Additionally, the company discussed ongoing projects, including a new radiation therapy center in Guadalajara, Mexico, set to start operations by the end of the year, and two new centers in Rhode Island, emphasizing strategic partnerships and recruitment efforts to drive future growth. Despite facing operational challenges and fluctuations, the company remains optimistic about its long-term growth trajectory and profitability, supported by a strong balance sheet with cash and cash equivalents at $11.3 million.American Shared Hospital Services Financial Statement Overview
Summary
American Shared Hospital Services shows mixed financial performance. Revenue growth is present, but profitability and cash flow generation are concerning. The balance sheet is stable with low leverage, but negative return on equity and cash flow challenges highlight the need for improved operational efficiency.Income Statement
The income statement shows a mixed performance. The TTM data reveals a slight revenue growth of 5.1%, but the company is struggling with profitability, as indicated by negative net profit and EBIT margins. The gross profit margin has decreased from previous years, reflecting challenges in maintaining cost efficiency. The revenue growth is positive, but the declining margins and negative net income are concerning.45
Neutral
Balance Sheet
The balance sheet indicates a relatively low debt-to-equity ratio of 0.15 in the TTM period, suggesting a conservative leverage approach. However, the return on equity is negative, reflecting the company's struggle to generate profits from its equity base. The equity ratio is stable, indicating a solid capital structure, but the negative ROE highlights profitability issues.60
Neutral
Cash Flow
Cash flow analysis shows a significant challenge with free cash flow, which is negative in the TTM period. Although operating cash flow is positive, the free cash flow to net income ratio is unfavorable, indicating inefficiencies in converting profits into free cash flow. The operating cash flow to net income ratio suggests some stability, but the negative free cash flow growth is a concern.50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.25M | 28.34M | 21.32M | 19.75M | 17.63M | 17.84M |
| Gross Profit | 7.15M | 9.08M | 9.34M | 8.38M | 6.73M | 4.47M |
| EBITDA | 3.66M | 8.91M | 6.97M | 8.44M | 6.97M | -1.43M |
| Net Income | -2.44M | 2.19M | 610.00K | 1.33M | 194.00K | -7.06M |
Balance Sheet | ||||||
| Total Assets | 63.49M | 60.20M | 48.16M | 43.96M | 45.43M | 43.65M |
| Cash, Cash Equivalents and Short-Term Investments | 11.08M | 11.03M | 13.69M | 12.34M | 8.14M | 3.96M |
| Total Debt | 3.64M | 21.91M | 15.68M | 13.82M | 16.13M | 14.40M |
| Total Liabilities | 34.65M | 30.17M | 21.88M | 18.33M | 21.19M | 20.00M |
| Stockholders Equity | 24.48M | 25.18B | 22.62M | 21.63M | 19.89M | 19.27M |
Cash Flow | ||||||
| Free Cash Flow | -8.58M | -7.77M | -555.00K | 6.85M | 4.59M | 9.29M |
| Operating Cash Flow | 2.88M | 167.00K | 5.72M | 7.24M | 6.27M | 9.74M |
| Investing Cash Flow | -10.98M | -7.11M | -6.27M | -388.00K | -1.67M | -2.39M |
| Financing Cash Flow | 4.95M | 4.41M | 1.91M | -2.66M | -655.00K | -4.81M |
American Shared Hospital Services Technical Analysis
Positive
2.90
Price Trends
2.53
Positive
2.51
Positive
2.74
Positive
Market Momentum
0.07
Negative
66.69
Neutral
83.01
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMS, the sentiment is Positive. The current price of 2.9 is above the 20-day moving average (MA) of 2.52, above the 50-day MA of 2.53, and above the 200-day MA of 2.74, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 66.69 is Neutral, neither overbought nor oversold. The STOCH value of 83.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMS.
American Shared Hospital Services Risk Analysis
American Shared Hospital Services disclosed 20 risk factors in its most recent earnings report. American Shared Hospital Services reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
American Shared Hospital Services Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $18.88M | 11.72 | -9.49% | ― | 26.61% | -156.30% | |
54 Neutral | 134.00M | -7.38 | -6.16% | ― | -41.31% | -163.08% | |
50 Neutral | 38.67M | -205.13 | 1.10% | 8.33% | 1.10% | 98.13% | |
48 Neutral | 70.15M | -0.20 | -178.90% | ― | 4.20% | -54.16% | |
46 Neutral | 27.03M | -0.63 | 13.52% | ― | -29.82% | -2.57% | |
40 Underperform | 2.56M | -0.01 | 523.15% | ― | -0.70% | -2.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
AMS
American Shared Hospital Services
2.90
-0.15
-4.92%
CCM
Concord Medical Services
6.22
-0.79
-11.27%
MODVQ
ModivCare
0.18
-14.10
-98.74%
CCEL
Cryo-Cell International
4.80
-1.02
-17.53%
DCGO
DocGo
1.37
-1.95
-58.73%
PIII
P3 Health Partners
9.76
-9.56
-49.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.